Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors

Radiotherapy and Oncology

Volumn 70, Issue 1, 2004, Pages 91-97

  Janssen, Hilde L K ^a   Hoebers, Frank J ^a   Sprong, Debbie ^a   Goethals, Laurence ^b   Williams, Kaye J ^c   Stratford, Ian J ^c   Haustermans, Karin M ^b   Balm, Alfons J ^a   Begg, Adrian C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Human; Hypoxia; Nitroreductase; Pimonidazole

Indexed keywords

ANTIBODY; CYTOCHROME P450 REDUCTASE; HYPOXYPROBE; NITROBLUE TETRAZOLIUM; PIMONIDAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER TISSUE; CELL HYPOXIA; CONTROLLED STUDY; FROZEN SECTION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KERATINIZATION; PRIORITY JOURNAL; SCORING SYSTEM; VALIDATION PROCESS; WILD TYPE;

EID: 0842324834     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2003.09.012     Document Type: Article

References (16)

1. Arteel G.E., Thurman R.G., Yates J.M., Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 72:1995;889-895.
2. Cobb L.M., Nolan J., Butler S. Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. Int J Radiat Oncol Biol Phys. 18:1990;347-351.
3. Cobb L.M., Nolan J., Hacker T. Retention of misonidazole in normal and malignant tissues: interplay of hypoxia and reductases. Int J Radiat Oncol Biol Phys. 22:1992;655-659.
4. el Gamoussi R., Threadgill M.D., Prade M., Stratford I.J., Guichard M. Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole. Cancer Chemother Pharmacol. 31:1993;277-282.
5. Garrecht B.M., Chapman J.D. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. Br J Radiol. 56:1983;745-753.
6. Janssen H.L., Haustermans K.M., Sprong D., et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys. 54:2002;1537-1549.
7. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62:2002;7066-7074.
8. Kennedy A.S., Raleigh J.A., Perez G.M., et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys. 37:1997;897-905.
9. Parliament M.B., Wiebe L.I., Franko A.J. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br J Cancer. 66:1992;1103-1108.
10. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58:1998;3765-3768.
11. Raleigh J.A., Chou S.C., Arteel G.E., Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 151:1999;580-589.
12. Raleigh J.A., Chou S.C., Calkins-Adams D.P., et al. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin Cancer Res. 6:2000;855-862.
13. Seip W.F., Evans G.L. Atmospheric analysis and redox potentials of culture media in the GasPak system. J Clin Microbiol. 11:1980;226-233.
14. Wijffels K.I., Kaanders J.H., Rijken P.F., et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer. 83:2000;674-683.
15. Cowen R.I., Patterson A.V., Telfer B.A., et al. Mol Cancer Ther. 2:2003;901-909.
16. Jaffar M., Phillips R.M., Williams K.J., et al. Biochem Pharmacol. 66:2003;1199-1206.